Skip to main content
Erschienen in: Journal of Cardiothoracic Surgery 1/2024

Open Access 01.12.2024 | Review

Pulmonary transplant complications: a radiologic review

verfasst von: Samuel Friedlander, Brian Pogatchnik, Yuka Furuya, Tadashi Allen

Erschienen in: Journal of Cardiothoracic Surgery | Ausgabe 1/2024

Abstract

Lung transplantation has become the definitive treatment for end stage respiratory disease. Numbers and survival rates have increased over the past decade, with transplant recipients living longer and with greater comorbidities, resulting in greater complexity of care. Common and uncommon complications that occur in the immediate, early, intermediate, and late periods can have significant impact on the course of the transplant. Fortunately, advancements in surgery, medical care, and imaging as well as other diagnostics work to prevent, identify, and manage complications that would otherwise have a negative impact on survivability. This review will focus on contextualizing complications both categorically and chronologically, with highlights of specific imaging and clinical features in order to inform both radiologists and clinicians involved in post-transplant care.
Hinweise

Supplementary Information

The online version contains supplementary material available at https://​doi.​org/​10.​1186/​s13019-024-02731-w.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
A1ATD
Alpha-1 antitrypsin deficiency
ACR
Acute cellular rejection
AMR
Antibody mediated rejection
ARAD
Azithromycin responsive allograft dysfunction
ARDS
Acute respiratory distress syndrome
BAL
Bronchoalveolar lavage
BCC
Burkholderia cepacia complex
BLT
Bilateral lung transplants
BOS
Bronchiolitis obliterans syndrome
C4d
Complement component 4d
CF
Cystic fibrosis
CLAD
Chronic lung allograft dysfunction
CMV
Cytomegalovirus
COPD
Chronic obstructive pulmonary disease
CT
Computed tomography
CTA
Computed tomography angiography
CTD
Connective tissue disease
DSA
Donor specific antigen
EBV
Epstein Barr virus
FEV1
Forced expiratory volume
FiO2
Fraction of inspired oxygen
FVC
Forced vital capacity
HLA
Human leukocyte antigen
ILD
Interstitial lung disease
ISHLT
International society for heart and lung transplantation
LAM
Lymphangioleiomyomatosis
MR
Magnetic resonance
mTOR
Mechanistic target-of-rapamycin
NTM
Non-tuberculous mycobacterium
PA
Pulmonary artery
PAH
Pulmonary arterial hypertension
PaO2
Partial pressure of oxygen
PAP
Pulmonary artery pressure
PCR
Polymerase chain reaction
PE
Pulmonary embolism
PET
Positron emission tomography
PGD
Primary graft dysfunction
PJP/PCP
Pneumocystis jirovecii pneumonia/pneumocystis pneumonia
PPFE
Pleuroparenchymal fibroelastosis
PTLD
Post-transplant lymphoproliferative disorder
RAS
Restrictive allograft syndrome
RV
Right ventricle
SLT
Single lung transplant
TB
Tuberculosis
TBM
Tracheobronchomalacia
TLC
Total lung capacity
VBIS
Vanishing bronchus intermedius syndrome
VTE
Venous thromboembolism

Introduction

Following the first human lung transplant performed by Dr. Hardy and his team at the University of Mississippi in 1963, the number of lung transplants has increased steadily, particularly over the last few decades [13]. From 2010–2018, approximately 34,000 were reported worldwide. Over half of those were done in North America alone [35]. Efforts to increase available donors have contributed to the rising rates of transplants. Worldwide, chronic obstructive pulmonary disease (COPD) is the most common indication for lung transplant, however in North America idiopathic pulmonary fibrosis (IPF) has supplanted COPD, followed by cystic fibrosis (CF) and alpha-1 antitrypsin deficiency (A1ATD) [3, 6].
In the early 2010s, the median, 1-, and 5-year survival rates had all increased from previous decades in part due to advancements such as infection prophylaxis, immunosuppression, and surgical techniques reducing incidence of morbid airway complications [710]. However, early complications remain dominated by infection and acute rejection, while chronic lung allograft dysfunction (CLAD), infection, and malignancy significantly affect late survival [7, 11]. Contributing to these complications are an increase in recipients of advanced age and low volume centers performing transplants [3, 7, 12]. Further, survival is lower than that of other solid organ transplant recipients [13].
Lung transplant recipients now live longer and are burdened with a greater number of comorbidities than in prior decades, lending to a greater volume and complexity of postoperative imaging. As imaging can support and potentially diagnose these complications, review of time-course specific features is of value to radiologists and transplant clinicians involved in post-transplant care [2, 14].

Overview of complications

Complications can be categorized based on time course (as well as specific imaging features or mechanism of pathology (Table 1, Fig. 1) [15]. An approximate timeline serves this purpose: immediate, early, intermediate, and late [15].
Table 1
Timing, Categorization, and Incidence of Posttransplant complications
Complication
Timing after surgery
Incidence
Mechanical
 Size mismatch
Preoperative-perioperative
60% of single lung transplants
50% of bilateral transplantsa
 Torsion
Days
Rare reports
Airway
 Bronchial dehiscence
Weeks-Months
1–10%
 Bronchial anastomotic stenosis
Months
1.6–32%
 Non-anastomotic stenosis
Months
2.5–3%
 TBM
Months
1–4%
Vascular
 Pulmonary embolism
Days-Months
1–19.5%, up to 27% on autopsy
 Arterial stenosis
Days-Months
 < 2%
 Venous stenosis
Days
1.4%
 Venous thrombosis
Days
2.5%
PGD
 
Hours-Days
30%
Pleural
 Simple effusion
Hours-Days
 
 Pneumothorax
Hours-Days
 
 Hemothorax
Hours-Days
 
 Chylothorax
Weeks
 < 1–11%
 Empyema
Weeks-Months
 
 Scarring
 Fibrosis
 Round atelectasis
Months
 
Infection
 Bacterial infection
Days
 
 B. Cepacia
Pre and perioperative
3–6% cystic fibrosis patients
 CMV
 PJP/PCP
 Fungal
 TB, NTM
Months
 
Immunologic
 Hyperacute rejection
Intraoperative-Hours postop
Rare reports
 ACR
Days-Weeks
27.3%
 AMR
Hours-Days
47%
 CLAD
Months-Years
50% at 5 years and 76% at 10 years
Recurrence
 Sarcoidosis (most common)
Months-Years
1/3 of sarcoidosis
1% overall
Malignancy
 PTLD
Months-Years
3–9%
 Primary lung cancer
Months-Years
1–9%
ACR Acute cellular rejection, AMR Antibody mediated rejection, B. Cepacia Burkholderia Cepacia, CLAD Chronic lung allograft dysfunction, CMV Cytomegalovirus, PJP/PCP Pneumocystis jirovecii pneumonia/pneumocystis pneumonia, PTLD Posttransplant lymphoproliferative disorder, NTM Nontuberculous mycobacteria, TB Tuberculosis, TBM Tracheobronchomalacia
aIn patients with chronic obstructive pulmonary disease and alpha 1 antitrypsin deficiency
Radiographs are ordered for preoperative baseline imaging and subsequently for evaluating support device positioning, complications such as effusions, edema, and infection, and after bronchoscopy [2, 16]. Radiographs are widely and immediately available in a range of clinical settings, deliver minimal radiation, and are highly cost effective. Computed tomography (CT) may be preferred for problem solving and specific clinical scenarios [2, 17]. Transplant specific imaging protocols after discharge are variable though routine radiography is suggested by some to screen for late complications [16, 17]. Therefore, radiographic assessment of complications are presented herein and highlighted, where possible, in the text and figures.

Mechanical

Size mismatch between donor allograft and recipient thoracic cavity can be apparent during surgery as well as in the immediate postoperative period, though prevention of significant size mismatch occurs during preoperative planning [2]. Size difference of up to 25% is acceptable for bilateral lung transplants (BLT); for single lung transplants (SLT), this is not well defined [18]. Rates of mismatch vary with indication for transplant, as the size of the thoracic cavity diverge between obstructive and restrictive lung disease. The 36th International Society for Heart and Lung Transplantation (ISHLT) report detailed that 60% of SLTs and 50% of BLTs for recipients with COPD/A1ATD came from oversized donors [6].
Recipients of oversized lungs can present with persistent hypoxemia and a requirement for prolonged mechanical ventilation that may be mitigated by graft volume reduction prior to implantation [19]. Oversized donor lungs can result in atelectasis and scarring once transplanted, while undersized donors can result in hyperinflation or persistent pleural complications such as pneumothorax and pleural effusion [2, 9].
Pulmonary torsion is reported primarily in case reports in the early postoperative period [2, 20]. Patients can present with acute cardiopulmonary instability consisting of increased pulmonary artery pressure (PAP), hypoxemia, and hypotension [21, 22]. Risk factors include an undersized allograft resulting in a large space for the lung to torse, complete fissures with separate lobes, and challenging cases requiring longer vascular conduits with greater manipulation and anatomic complexity [2, 20]. Radiography reveals a change in lobar positioning with atelectasis/consolidation and hilar displacement over subsequent exams [2, 21]. Contrast enhanced CT or CT angiography (CTA) better depicts these findings in addition to swirling, abnormal positioning, or cutoff of the vascular pedicle and bronchi [2, 14, 15, 20]. Due to its infrequency it has the potential to be misdiagnosed and lead to infarction and rejection if surgical correction is not performed within 12 hours [2, 14, 15, 20].

Airway

The 2018 ISHLT consensus on airway complications reported an incidence of 2–18% based on recent studies [23]. Mortality is 2–4% [24]. The pathophysiology involves decreased systemic blood supply and relative ischemia in the immediate postoperative period [9, 15]. Anastomotic blood flow is dependent on low retrograde flow from the pulmonary arterial supply at the time of surgery, as bronchial arterial supply is not often surgically re-established [25]. Bronchial neovascularization takes up to 6 weeks [23, 25].
Anastomotic dehiscence most commonly occurs within the first month after surgery [2, 15]. Incidence is 1–10%, which has decreased from prior decades [23, 25]. Despite this, many centers still report high morbidity and mortality associated with severe cases of dehiscence [23, 24, 2628].
Risk factors that promote ischemia include infection, prolonged ventilation, primary graft dysfunction (PGD), use of certain immunosuppressants (mechanistic target-of-rapamycin (mTOR) inhibitors), and surgical technique – a long bronchial donor stump, short recipient, and telescoping anastomosis [14, 29].
Dehiscence can present as persistent air leaks, subcutaneous emphysema, or need for prolonged mechanical ventilation [29]. Radiographs usually suggest dehiscence indirectly by the persistent or delayed appearance of extraluminal air [2, 29]. Persistent atelectasis and infection are also consequences of dehiscence [29]. CT depicts the anastomotic defect with bronchial wall irregularity and extraluminal peribronchial air, pneumomediastinum, and pneumothorax [29, 30]. A focal anastomotic contour abnormality alone is also possible (Fig. 2). Flexible or rigid bronchoscopy is performed for diagnosis, and, in some cases, intervention [2, 14, 29].
Bronchial stenosis is the most common airway complication, and usually presents after 2–3 months [2, 14]. Incidence ranges from 1.6–32%, with a wide range due to heterogeneous reporting prior to the 2018 ISHLT consensus [2325, 29]. Central airway stenosis affects the region within 2 cm of the anastomosis, with rarer reports of distal/non-anastomotic stenosis beyond 2 cm [23]. Associations include healed dehiscence, infection, telescoping anastomosis, and repetitive trauma from bronchoscopy [15, 29]. Patients may present with wheezing, asymptomatic airflow obstruction on spirometry, productive cough, and in cases of complete occlusion, post-obstructive pneumonia [29, 30]. Radiographs depict post obstructive lobar atelectasis and pneumonia [31]. CT will demonstrate fixed anastomotic narrowing (Fig. 3) [15, 29]. > 50% reduction in cross-sectional area is considered significant [23].
Distal/non-anastomotic stenosis is reported in 2.5–3% of transplants [29]. The most commonly described form is vanishing bronchus intermedius syndrome (VBIS) and occurs approximately 6 months after transplant [29]. Risk factors include ischemia and infection, though the exact cause is not known [23]. VBIS presents with persistent fever, pneumonia, and airflow obstruction, with imaging demonstrating post-obstructive atelectasis or air trapping (Fig. 4) [14]. > 50% luminal area narrowing is significant [23], with the bronchus intermedius most commonly involved secondary to its narrow lumen [14]. Although imaging can aid in diagnosis of airway stenoses, bronchoscopy is confirmatory and allows for intervention [29].
Tracheobronchomalacia (TBM) has an incidence of 1–4% and occurs within 4 months after transplant [24, 29]. Pathologically it is defined as > 50% luminal area reduction with expiration, within 1 cm of the anastomosis (peri-anastomotic), or beyond (diffuse) [25]. Some have reported TBM’s association with airway stenosis, and diffuse TBM with bronchiolitis obliterans syndrome (BOS) [29]. Risk factors include prolonged intubation, inflammation, recurrent infections, and trauma [32]. The exact mechanism is unknown but involves the loss of cartilaginous airway support [2, 29].
TBM can present with dyspnea, productive cough, and variable airflow obstruction on spirometry [29]. Imaging can aid in diagnosis, and CT protocols that include dynamic exhalation and virtual bronchoscopy reconstructions improve visualization of airway collapse and prevent underestimation of luminal narrowing and length of involvement (Supplementary Tables 1 and 2) [10, 3234]. The primary finding is airway collapse with expiration, with an additional qualitative feature of collapse of the anterolateral cartilaginous rings (Fig. 3) [32]. An incidentally discovered lunate shaped trachea on routine/inspiratory CT should raise suspicion for TBM [34]. The severity of collapse and presence of concomitant infection or rejection may influence treatment [25]. Bronchoscopy with visualization of airway collapse during expiration remains the gold standard for diagnosis [29].

Vascular

Vascular anastomotic complications are reported in 2–15% of transplants [35, 36]. Pulmonary embolism (PE) and arterial stenosis are the most common [36]. Clinical features consist of unexplained hypoxemia or prolonged need for mechanical ventilation, dyspnea, pulmonary hypertension, and hemodynamic compromise [36]. A high index of suspicion is needed, especially for rare complications such as vascular stenosis, as signs and symptoms can be indistinguishable from other early post-transplant complications such as infection or PGD [36].
PE is most common in the early and intermediate postoperative time periods. In lung transplant recipients there is higher incidence, morbidity, and mortality from venous thromboembolism (VTE), including deep venous thrombosis and PE, thought to be a result of poor or absent collateralization of bronchial circulation [2, 30, 35, 36]. Reported post-transplant incidence is 1–19.5% compared to 1.6% in the general surgical population [3638]. Risk factors include older age, diabetes, recent pneumonia, use of immunosuppressants such as sirolimus, and prolonged mechanical ventilation [39, 40].
Symptoms include tachycardia, dyspnea, cough, and hemoptysis [30]. Radiographic findings are neither specific nor sensitive. On CT pulmonary angiogram, a filling defect within or occlusion of the pulmonary arteries is diagnostic. Secondary features include oligemia, mosaic attenuation, and/or wedge-shaped subpleural consolidative or ground glass opacities representing infarcts (Fig. 5) [30, 41].
In retrospective studies, PE was independently associated with greater in-hospital death compared to those without VTE [42], and within the first 180 days, strongly associated with bronchial stenosis and CLAD [43]. Complications include infarction and graft loss [2, 30, 36]. The risk of pulmonary infarction is greater than in the general population due to delayed bronchial revascularization, with incidence up to 37.5% [38, 44]. Infarction may be associated with cavitation (Fig. 5), with resultant empyema, abscess, bronchopleural fistula, and pneumothorax [44, 45].
Arterial anastomotic stenosis can be seen both early and late after transplant and occurs in less than 2% of cases [36]. Risk factors include a short allograft artery, long vascular pedicle, suturing technique, or thrombus, in combination with natural tortuosity of the pulmonary arteries [15, 36]. A systematic review found an estimated mortality rate of 22.6% [46].
Clinical presentation includes hypoxemia, pulmonary artery hypertension (PAH), and hemodynamic compromise including hypotension [46]. CT and magnetic resonance (MR) angiography show focal narrowing at the anastomosis (Fig. 6), and nuclear medicine ventilation perfusion imaging shows a perfusion defect with intact ventilation, or ventilation/perfusion mismatch [15]. 75% anastomotic diameter narrowing is hemodynamically significant. Interstitial edema and pleural effusions are commonly associated [36].
Pulmonary vein thrombosis is an early complication [15, 36]. A recent systematic review reported incidence and mortality of 2.5% and 24% respectively among a total of 1,618 transplants from 34 studies. Risk factors are not well established [47]. A filling defect on delayed venous phase chest CT is diagnostic. Secondary imaging findings include persistent parenchymal opacities and pulmonary edema [15]. Complications include infarct, allograft failure, and stroke via systemic embolization [48].
Venous anastomotic stenosis occurs early, within days [15, 30]. Stenosis is currently without standardized criteria for diagnosis. A case report identified 18 cases from the literature [49], while a systematic review of the literature reported a prevalence of 1.4%, with an estimated mortality rate of 45% [47]. Pulmonary venous thrombosis is a risk factor [36]. Radiographs show airspace opacification confined to the affected lobe. Delayed venous phase CT demonstrates focal anastomotic diameter narrowing, greater than the expected 1–2 mm folds, most commonly at the left inferior pulmonary vein [36]. Secondary signs include consolidations, ground glass opacities, and interlobular septal thickening representing interstitial edema [15, 30, 36].
Patients with PAH receiving transplants can expect normalization of pulmonary artery (PA) dilation over a period of months, which correlates with normalized PAPs [50]. Right ventricular (RV) dysfunction should immediately improve, while characteristics of severe dysfunction that can be noted on imaging such as RV dilation, RV hypertrophy, and pericardial effusion should decrease or resolve over months [51]. Conundrums include a higher prevalence of PGD and edema in the early setting and PA dilation due to size mismatch, PAH recurrence, or the aforementioned vascular complications such as anastomotic stenosis [36, 52]. CTA and CT venography are adjuncts to echocardiography and right heart catheterization and can evaluate patency and size of the pulmonary vasculature, the anastomoses, and lung parenchyma [32].

Primary graft dysfunction

PGD can occur in the early to intermediate postoperative period, usually radiographically evident at 24–72 h with resolution by 5–10 days [2]. PGD requires exclusion of other causes of acute respiratory distress syndrome (ARDS) [2, 11]. The 2005 ISHLT consensus statement and subsequent 2016 revision defined PGD based on PaO2 to FiO2 ratio, radiologic findings of pulmonary edema, timing of presentation, and exclusion of other pathologies including infection, hyperacute rejection, and cardiogenic pulmonary edema [11].
Estimated incidence is 30% [53]. A single center retrospective review which looked at incidence and outcome of grade 3 PGD utilizing the 2016 criteria showed a 90-day mortality of 8.5% and a 1-year mortality of 25.5% [54, 55]. PGD is associated with many risk factors, among which include a prolonged ischemic time of the donor allograft and hemodynamic instability after brain death [53, 56]. A preoperative diagnosis of PAH is also a significant risk factor [55, 57].
Presentation and imaging features are similar to ARDS [30], including mid to lower lung perihilar airspace opacities on radiograph and diffuse consolidative or mixed consolidative and ground glass opacities, interlobular and peribronchial interstitial thickening on CT (Fig. 7) [2]. PGD has a significant impact on both early and late prognoses, including its association with later development of BOS. PGD is a clinical diagnosis and thus transbronchial biopsies are not routinely performed [2, 11].

Pleural

Pleural effusion and pneumothorax are common in the immediate postoperative period. Persistent air leak beyond one week may lead to persistent/increasing pneumothorax, pneumomediastinum, and subcutaneous emphysema on subsequent radiographs, which would require investigation for a causative airway complication [14, 31]. Persistent/increased effusions should suggest pathology such as hemothorax, chylothorax, and empyema [58]. Clinical presentations of pleural complications vary based on etiology. Any large volume effusion will produce mass effect and patients may experience non-specific symptoms such as dyspnea and cough [59].
Hemothorax usually occurs in the early post-operative period. CT will demonstrate hyperdense pleural fluid of 35–70 Hounsfield units. Rapid pleural fluid accumulation on early radiographs is another sign of hemothorax (Fig. 8) and would likely require an emergent return to the operating room if in the early postoperative period [2, 15].
Chylothorax presents as a persistent or increasing effusion despite adequate chest tube drainage, though cannot be specifically diagnosed based on imaging features and requires pleural fluid analysis [15]. Elevated pleural triglycerides, chylomicrons, and lymphocytes are diagnostic (Fig. 9) [15]. Incidence from small cohort studies ranged from < 1–11%. Extensive pleural adhesions from prior infection or pleurodesis can increase risk of thoracic duct injury. Chylothorax is prevalent among patients with lymphangioleiomyomatosis (LAM) [60].
As infectious complications are common in this population, empyema should be considered and ruled out in the setting of a new pleural effusion, especially with loculation [2, 15]. While uncommon, it has been to shown to increase mortality [61, 62]. On CT, it appears as a loculated or lenticular shaped effusion with pleural thickening and enhancement resulting in the split pleura sign [15].

Infection

Early infections are most commonly bacterial, and infection is the most significant factor of morbidity and mortality within the first year, although it remains an important complication to consider even afterwards [10, 16, 63]. In addition, infections and colonization with organisms such as Pseudomonas, Cytomegalovirus (CMV), and Aspergillus, have been linked to higher rates of CLAD and acute rejection [64]. Bronchoscopy with bronchoalveolar lavage (BAL) and transbronchial biopsies are useful adjuncts to the diagnosis of bacterial and opportunistic infections [63, 65]. Tracheobronchial infections are often found incidentally on surveillance bronchoscopies, however if narrowing of the airway occurs due to fibrinous debris or mucus, patients may present with signs of airway obstruction such as a drop in FEV1, dyspnea, and/or wheezing [29, 64].
Bacterial infection is the leading cause of mortality up to 6 months [10]. Risk factors for infection include immunosuppression, prolonged mechanical ventilation, and bronchial mucosal ischemia [66]. While radiograph is often first line imaging, CT will reveal consolidations, pleural effusions, centrilobular nodules, tree-in-bud opacities, and interlobular septal thickening with greater sensitivity [16, 63].
Burkholderia cepacia complex (BCC) affects 3–6% of CF patients [67]. The specific genomovar III, B cenocepacia, has the highest incidence of “cepacia syndrome,” which presents with necrotizing pneumonia and sepsis [67, 68]. Up to 80% mortality at 1 year has been documented in retrospective studies [67]. CF patients are the most likely to be colonized with BCC, and can undergo a rapid decline in lung function as well as cepacia syndrome. Most transplant centers consider BCC colonization an absolute contraindication to transplant in CF patients due to decreased survivability [6769]. CT showing mucoid impaction suggests BCC colonization, while rapid progression of bronchiectasis and consolidations correlates with either graft function decline or cepacia syndrome (Fig. 10) [7072].
Viral and fungal infections occur late after transplant. The most common viral pneumonia is due to CMV, which takes place in the setting of seronegative mismatch (seronegative recipient and seropositive donor) and/or non-adherence to prophylaxis [2, 63]. Widespread use of prophylaxis as well as quantitative polymerase chain reaction (PCR) assays monitoring for viremia has resulted in decreased incidence [63]. In immunosuppressed transplant patients, clinical presentation can range from non-specific features such as myalgia, arthralgia, and leukopenia to multi-organ system involvement [63]. Imaging findings include ground glass opacities or consolidations, as well as diffuse nodular pattern with tree-in-bud opacities [2, 16, 73].
Typical CT features of fungal infections are nodular ground glass or consolidative opacities, including the “halo” sign of consolidations with peripheral ground glass [2]. Pneumocystis jirovecii pneumonia (PJP/PCP), like CMV, is more common with non-adherence to prophylaxis [14]. Patients typically present with hypoxemia out of proportion to other clinical findings [63]. Typical imaging findings are bilateral subpleural sparing ground glass opacities (Fig. 11), with interlobular septal thickening, nodular opacities, and apical predominant cystic lesions that can result in pneumothorax and pneumomediastinum [14].
Late-presenting infections include tuberculosis (TB) and non-tuberculous mycobacterial infection (NTM), with lung transplant recipients at higher risk compared to other solid organ recipients [64]. CT of mycobacterial infection shows centrilobular or tree in bud nodules, miliary nodular pattern, consolidations, bronchiectasis, and cavitations [10]. NTM, commonly including Mycobacterium abscessus, results in increased mortality [63, 64]. The diagnosis of NTM infection requires specific radiologic findings and positive sputum culture, BAL, or transbronchial biopsy [63, 74].
Retrospective studies report severe presentation and higher mortality rates in transplant recipients with COVID-19 compared to the general population [64, 75]. Radiologic findings are similar whether transplanted lungs are present or not (Fig. 12). Confounding features are possible in patients with SLTs with native lung fibrosis or emphysema [76]. Recent studies with at least 6 month follow up of these patients demonstrated allograft function decline following severe COVID-19 infection [77, 78]. New cases of CLAD including BOS and restrictive allograft syndrome (RAS) phenotypes have been reported, with prior studies demonstrating a link between viral pneumonia and CLAD [79, 80]. Long term follow-up should establish whether allograft dysfunction and imaging findings are permanent [76, 77].

Immunologic

Hyperacute rejection is primarily described in case reports, as most cases are averted through anti-HLA antibody screening and avoidance of organs bearing those specific HLA antigens [30]. It presents intraoperatively or within the first few hours after the vascular anastomosis is created [10], due to rejection by antibodies reactive to the allograft already in the recipient’s circulation [81]. It can present as severe and refractory hypoxemia [2], with rapid airspace opacification on imaging [10].
Acute cellular rejection (ACR) most commonly occurs in the early period, radiographically evident by 5–10 days, though still possible weeks to months after transplant [2, 10]. The pathophysiology involves a T-cell mediated immune response by the recipient against donor allograft antigens [2, 15]. 27.3% of transplant recipients had a previously treated episode of acute rejection at one year in the 2019 ISHLT report. 2.7 and 1.9% of all transplant patient deaths at 30 days and 1 year respectively were attributed to acute rejection [6, 82].
Presentation is similar to infection, including dyspnea, fever, and leukocytosis [30]. At imaging, CT shows interlobular septal thickening, centrilobular ground glass opacities, and scattered to diffuse areas of ground glass and consolidative opacities [2, 15]. Despite this, CT has limited detection of acute rejection and as such tissue sampling via transbronchial biopsy is required for diagnosis [2, 83]. There is a strong association with the development of BOS [84].
The 2016 ISHLT consensus report on antibody-mediated rejection (AMR) provided standardized diagnostic criteria, including allograft dysfunction, the presence of donor specific antigens (DSA), and suggestion of AMR on histology including positive staining for complement component 4d (C4d) [81]. While associated with hyperacute and acute forms of rejection, AMR also appears weeks to months out from transplantation. Antibodies specific to the allograft may be pre-formed prior to actual transplantation particularly in the setting of hyperacute rejection, while AMR outside the hyperacute setting is typically the result of sensitization to DSAs after transplantation [84]. A recent multicenter prospective study found an incidence of 47% among 335 lung transplants, including clinical and subclinical AMR. Significantly increased risk of CLAD and death was also found [85].
Imaging findings of AMR are nonspecific, with ground glass opacities and air trapping on expiratory CT reported in certain studies. Imaging is more useful in the exclusion of other etiologies such as infection [85, 86]. Transbronchial biopsy may be helpful, although the appearance of certain histological features such as pulmonary capillary injury may be non-specific [87, 88]. AMR and DSA positivity are associated with CLAD [81, 87].
CLAD is defined as persistent ≥ 20% decline in FEV1 from baseline, through obstructive, restrictive, mixed, or undefined patterns on pulmonary function tests (PFTs) [89]. The most common presenting phenotypes are BOS and RAS (Fig. 13) [2, 89]. The incidence of CLAD is 50% at 5 years and 76% at 10 years [82]. Risk factors include PGD, ACR, AMR, gastroesophageal reflux, infection, and non-adherence to immunosuppressive medications [30]. Glucagon-like peptide-1 receptor agonists, used to treat solid organ recipients with diabetes mellitus, can cause gastroparesis and intensify gastrointestinal complications commonly seen in patients on certain immunosuppressants, theoretically leading to poor tolerance [90].
BOS is characterized by an obstructive (FEV1/FVC < 0.7) spirometry pattern without restriction [89]. BOS comprises 65–75% of cases of CLAD with an incidence of 8.8% at 1 year and 41.1% at 5 years, with median survival of 3–5 years [89, 91]. CT shows expiratory air trapping, bronchial wall thickening, and bronchiectasis (Fig. 13). Other than to exclude other causes of decline in spirometry, bronchoscopy and histopathology have limited utility in diagnosis [2, 30, 91]. The use of quantitative imaging in combination with a radiologist’s qualitative analysis has also been shown to increase diagnostic performance in distinguishing BOS from other entities [92].
Diagnostic criteria for RAS include a restrictive pattern in spirometry (persistent ≥ 10% decline of TLC from baseline), absence of airflow obstruction, and persistent opacities on imaging [89]. RAS comprises 25–35% of CLAD cases with a median survival of 6–18 months [91]. The incidence of RAS and mixed phenotypes is 14–26% [93]. Both PFT and radiologic abnormalities persist despite treatment [15, 30, 91]. Histopathology reveals either acute inflammation or pleuroparenchymal fibroelastosis (PPFE). Radiologic features of PPFE include apical predominant pleural thickening with subjacent reticular opacities, traction bronchiectasis, and architectural distortion (Fig. 13) [94, 95].

Primary recurrence

Recurrence of primary disease may occur months to years after surgery [30]. A multicenter retrospective study [96] showed 1% recurrence in 1,354 transplant recipients. Sarcoidosis was the most common to recur, in approximately 33% of cases. Imaging of recurrent sarcoid shows solitary, perilymphatic, or miliary nodules, and lymphadenopathy [96]. Other reported examples of recurrence include LAM and pulmonary alveolar proteinosis [14, 30].
While interstitial lung disease (ILD) makes up approximately 40% of transplant indications [3, 6], recurrence is infrequently reported in the literature, especially connective tissue disease (CTD) associated ILD (CTD-ILD) (Fig. 14), hypersensitivity pneumonitis, and desquamative interstitial pneumonia. Risk factors are unknown [52]. A high index of suspicion is necessary in transplant recipients with either a history of or suspected CTD/CTD-ILD [97].

Malignancy

Posttransplant lymphoproliferative disorder (PTLD) represents a heterogeneous group of lymphoid disorders, and involves the allografts as early as 1 month, though typically within the first year after transplant, with a greater incidence in Epstein-Barr virus (EBV) seronegative and immunocompromised populations [30, 98]. Incidence is between 3–9% [98], with mortality at 30–75% [99]. The most common intrathoracic radiologic manifestations of PTLD include homogenous solitary intraparenchymal mass or solitary or multiple nodules, less commonly intrathoracic lymphadenopathy [30]. Findings are hypermetabolic on positron emission tomography(PET)-CT [30] (Fig. 15) which increases sensitivity and staging accuracy [99]. The imaging features in combination with the timing of clinical presentation, lab abnormalities, and allograft dysfunction should direct toward the need for tissue sampling [100].
Immunosuppression contributes to increased risk of development and progression of primary lung neoplasm [30]. Lung cancer rates are up to 5.5 times higher than that of the general population, with incidence of 1–9% [2, 98]. Transplant recipients have higher morbidity and mortality [98]. Pulmonary malignancy can be found de novo, in the native lung from SLTs, incidentally from lung explants, or recurrent. Donor malignancy is rare [98].

Conclusion

While the numbers of transplants performed have been increasing, improvement in survival still lags behind other solid organ transplant recipients. Radiology can play a crucial role in screening for and detecting transplant complications, a significant cause of recipient morbidity and mortality. Therefore, it is crucial for both radiologists and transplant clinicians to have a broad awareness of the timeline and diagnostic findings of possible complications.

Acknowledgements

Not applicable.

Declarations

Not applicable.
Not applicable.

Competing interests

The authors declare no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
2.
Zurück zum Zitat Kim SJ, Azour L, Hutchinson BD, Shirsat H, Zhou F, Narula N, et al. Imaging Course of Lung Transplantation: From Patient Selection to Postoperative Complications. Radiographics. 2021;41(4):1043–63.PubMedCrossRef Kim SJ, Azour L, Hutchinson BD, Shirsat H, Zhou F, Narula N, et al. Imaging Course of Lung Transplantation: From Patient Selection to Postoperative Complications. Radiographics. 2021;41(4):1043–63.PubMedCrossRef
3.
Zurück zum Zitat Chambers D, Perch M, Zuckermann A, Cherikh W, Harhay M, Hayes D, et al. The international thoracic organ transplant registry of the international society for heart and lung transplantation: Thirty-eighth adult lung transplantation report - 2021; Focus on recipient characteristics. J Heart Lung Transplant. 2021;40(10):1060–72. https://doi.org/10.1016/j.healun.2021.07.021. Chambers D, Perch M, Zuckermann A, Cherikh W, Harhay M, Hayes D, et al. The international thoracic organ transplant registry of the international society for heart and lung transplantation: Thirty-eighth adult lung transplantation report - 2021; Focus on recipient characteristics. J Heart Lung Transplant. 2021;40(10):1060–72. https://​doi.​org/​10.​1016/​j.​healun.​2021.​07.​021.
4.
Zurück zum Zitat Perch M, Hayes D, Cherikh W, Zuckermann A, Harhay M, Hsich E, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-ninth adult lung transplantation report—2022; focus on lung transplant recipients with chronic obstructive pulmonary disease. J Heart Lung Transplant. 2022;41(10):1335–47.PubMedPubMedCentralCrossRef Perch M, Hayes D, Cherikh W, Zuckermann A, Harhay M, Hsich E, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-ninth adult lung transplantation report—2022; focus on lung transplant recipients with chronic obstructive pulmonary disease. J Heart Lung Transplant. 2022;41(10):1335–47.PubMedPubMedCentralCrossRef
5.
Zurück zum Zitat Valapour M, Lehr CJ, Skeans MA, Smith JM, Miller E, Goff R, et al. OPTN/SRTR 2019 Annual Data Report: Lung. Am J Transplant. 2021;21(S2):441–520.PubMedCrossRef Valapour M, Lehr CJ, Skeans MA, Smith JM, Miller E, Goff R, et al. OPTN/SRTR 2019 Annual Data Report: Lung. Am J Transplant. 2021;21(S2):441–520.PubMedCrossRef
6.
Zurück zum Zitat Chambers DC, Cherikh WS, Harhay MO, Hayes D, Hsich E, Khush KK, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart–lung transplantation Report—2019; Focus theme: Donor and recipient size match. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2019;38(10):1042–55.CrossRef Chambers DC, Cherikh WS, Harhay MO, Hayes D, Hsich E, Khush KK, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart–lung transplantation Report—2019; Focus theme: Donor and recipient size match. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2019;38(10):1042–55.CrossRef
7.
Zurück zum Zitat Bos S, Vos R, Van Raemdonck DE, Verleden GM. Survival in adult lung transplantation: where are we in 2020? Curr Opin Organ Transplant. 2020;25(3):268–73.PubMedCrossRef Bos S, Vos R, Van Raemdonck DE, Verleden GM. Survival in adult lung transplantation: where are we in 2020? Curr Opin Organ Transplant. 2020;25(3):268–73.PubMedCrossRef
8.
Zurück zum Zitat Date H, Trulock EP, Arcidi JM, Sundaresan S, Cooper JD, Patterson GA. Improved airway healing after lung transplantation: An analysis of 348 bronchial anastomoses. J Thorac Cardiovasc Surg. 1995;110(5):1424–33.PubMedCrossRef Date H, Trulock EP, Arcidi JM, Sundaresan S, Cooper JD, Patterson GA. Improved airway healing after lung transplantation: An analysis of 348 bronchial anastomoses. J Thorac Cardiovasc Surg. 1995;110(5):1424–33.PubMedCrossRef
9.
Zurück zum Zitat Li Ng Y, Paul N, Patsios D, Walsham A, Chung TB, Keshavjee S, et al. Imaging of Lung Transplantation: Review. Am J Roentgenol. 2009;192(3_supplement):S1-13.CrossRef Li Ng Y, Paul N, Patsios D, Walsham A, Chung TB, Keshavjee S, et al. Imaging of Lung Transplantation: Review. Am J Roentgenol. 2009;192(3_supplement):S1-13.CrossRef
10.
Zurück zum Zitat Amadi CC, Galizia MS, Mortani Barbosa EJ. Imaging Evaluation of Lung Transplantation Patients: A Time and Etiology-based Approach to High-resolution Computed Tomography Interpretation. J Thorac Imaging. 2019;34(5):299–312.PubMedCrossRef Amadi CC, Galizia MS, Mortani Barbosa EJ. Imaging Evaluation of Lung Transplantation Patients: A Time and Etiology-based Approach to High-resolution Computed Tomography Interpretation. J Thorac Imaging. 2019;34(5):299–312.PubMedCrossRef
11.
Zurück zum Zitat Snell GI, Yusen RD, Weill D, Strueber M, Garrity E, Reed A, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, part I: Definition and grading—A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2017;36(10):1097–103.PubMedCrossRef Snell GI, Yusen RD, Weill D, Strueber M, Garrity E, Reed A, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, part I: Definition and grading—A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2017;36(10):1097–103.PubMedCrossRef
12.
Zurück zum Zitat Raskin J, Vanstapel A, Verbeken EK, Beeckmans H, Vanaudenaerde BM, Verleden SE, et al. Mortality after lung transplantation: a single-centre cohort analysis. Transpl Int. 2020;33(2):130–41.PubMedCrossRef Raskin J, Vanstapel A, Verbeken EK, Beeckmans H, Vanaudenaerde BM, Verleden SE, et al. Mortality after lung transplantation: a single-centre cohort analysis. Transpl Int. 2020;33(2):130–41.PubMedCrossRef
14.
Zurück zum Zitat Tejwani V, Panchabhai TS, Kotloff RM, Mehta AC. Complications of Lung Transplantation. Chest. 2016;149(6):1535–45.PubMedCrossRef Tejwani V, Panchabhai TS, Kotloff RM, Mehta AC. Complications of Lung Transplantation. Chest. 2016;149(6):1535–45.PubMedCrossRef
15.
Zurück zum Zitat Jokerst C, Sirajuddin A, Mohammed TL. Imaging the Complications of Lung Transplantation. Radiol Clin North Am. 2016;54(2):355–73.PubMedCrossRef Jokerst C, Sirajuddin A, Mohammed TL. Imaging the Complications of Lung Transplantation. Radiol Clin North Am. 2016;54(2):355–73.PubMedCrossRef
16.
Zurück zum Zitat Hemmert C, Ohana M, Jeung MY, Labani A, Dhar A, Kessler R, et al. Imaging of lung transplant complications. Diagn Interv Imaging. 2014;95(4):399–409.PubMedCrossRef Hemmert C, Ohana M, Jeung MY, Labani A, Dhar A, Kessler R, et al. Imaging of lung transplant complications. Diagn Interv Imaging. 2014;95(4):399–409.PubMedCrossRef
17.
Zurück zum Zitat Garg K, Zamora MR, Tuder R, Armstrong JD, Lynch DA. Lung transplantation: indications, donor and recipient selection, and imaging of complications. Radiographics. 1996;16(2):355–67.PubMedCrossRef Garg K, Zamora MR, Tuder R, Armstrong JD, Lynch DA. Lung transplantation: indications, donor and recipient selection, and imaging of complications. Radiographics. 1996;16(2):355–67.PubMedCrossRef
18.
Zurück zum Zitat Orens JB, Boehler A, de Perrot M, Estenne M, Glanville AR, Keshavjee S, et al. A review of lung transplant donor acceptability criteria. J Heart Lung Transplant. 2003;22(11):1183–200.PubMedCrossRef Orens JB, Boehler A, de Perrot M, Estenne M, Glanville AR, Keshavjee S, et al. A review of lung transplant donor acceptability criteria. J Heart Lung Transplant. 2003;22(11):1183–200.PubMedCrossRef
19.
Zurück zum Zitat Shigemura N, Bermudez C, Hattler B, Johnson B, Crespo M, Pilewski J, et al. Impact of Graft Volume Reduction for Oversized Grafts After Lung Transplantation on Outcome in Recipients With End-stage Restrictive Pulmonary Diseases. J Heart Lung Transplant. 2009;28(2):130–4.PubMedCrossRef Shigemura N, Bermudez C, Hattler B, Johnson B, Crespo M, Pilewski J, et al. Impact of Graft Volume Reduction for Oversized Grafts After Lung Transplantation on Outcome in Recipients With End-stage Restrictive Pulmonary Diseases. J Heart Lung Transplant. 2009;28(2):130–4.PubMedCrossRef
20.
Zurück zum Zitat Gilkeson RC, Lange P, Kirby TJ. Lung Torsion After Lung Transplantation. Am J Roentgenol. 2000;174(5):1341–3.CrossRef Gilkeson RC, Lange P, Kirby TJ. Lung Torsion After Lung Transplantation. Am J Roentgenol. 2000;174(5):1341–3.CrossRef
21.
Zurück zum Zitat Grazia TJ, Hodges TN, Cleveland JC, Sheridan BC, Zamora MR. Lobar torsion complicating bilateral lung transplantation. J Heart Lung Transplant. 2003;22(1):102–6.PubMedCrossRef Grazia TJ, Hodges TN, Cleveland JC, Sheridan BC, Zamora MR. Lobar torsion complicating bilateral lung transplantation. J Heart Lung Transplant. 2003;22(1):102–6.PubMedCrossRef
22.
Zurück zum Zitat Lopes S, Maciel J, Pinho P. When lobar torsion is on the left. Surgery. 2019;165(6):1243.CrossRef Lopes S, Maciel J, Pinho P. When lobar torsion is on the left. Surgery. 2019;165(6):1243.CrossRef
23.
Zurück zum Zitat Crespo MM, McCarthy DP, Hopkins PM, Clark SC, Budev M, Bermudez CA, et al. ISHLT Consensus Statement on adult and pediatric airway complications after lung transplantation: Definitions, grading system, and therapeutics. J Heart Lung Transplant. 2018;37(5):548–63.PubMedCrossRef Crespo MM, McCarthy DP, Hopkins PM, Clark SC, Budev M, Bermudez CA, et al. ISHLT Consensus Statement on adult and pediatric airway complications after lung transplantation: Definitions, grading system, and therapeutics. J Heart Lung Transplant. 2018;37(5):548–63.PubMedCrossRef
26.
Zurück zum Zitat Kshettry VR, Kroshus TJ, Hertz MI, Hunter DW, Shumway SJ, Bolman RM. Early and Late Airway Complications After Lung Transplantation: Incidence and Management. Ann Thorac Surg. 1997;63(6):1576–83.PubMedCrossRef Kshettry VR, Kroshus TJ, Hertz MI, Hunter DW, Shumway SJ, Bolman RM. Early and Late Airway Complications After Lung Transplantation: Incidence and Management. Ann Thorac Surg. 1997;63(6):1576–83.PubMedCrossRef
27.
Zurück zum Zitat Mughal MM, Gildea TR, Murthy S, Pettersson G, DeCamp M, Mehta AC. Short-Term Deployment of Self-Expanding Metallic Stents Facilitates Healing of Bronchial Dehiscence. Am J Respir Crit Care Med. 2005;172(6):768–71.PubMedCrossRef Mughal MM, Gildea TR, Murthy S, Pettersson G, DeCamp M, Mehta AC. Short-Term Deployment of Self-Expanding Metallic Stents Facilitates Healing of Bronchial Dehiscence. Am J Respir Crit Care Med. 2005;172(6):768–71.PubMedCrossRef
28.
Zurück zum Zitat Furukawa M, Chan EG, Morrell MR, Ryan JP, Rivosecchi RM, Iasella CJ, et al. Risk factors of bronchial dehiscence after primary lung transplantation. J Card Surg. 2022;37(4):950–7.PubMedCrossRef Furukawa M, Chan EG, Morrell MR, Ryan JP, Rivosecchi RM, Iasella CJ, et al. Risk factors of bronchial dehiscence after primary lung transplantation. J Card Surg. 2022;37(4):950–7.PubMedCrossRef
29.
Zurück zum Zitat Santacruz JF, Mehta AC. Airway Complications and Management after Lung Transplantation: Ischemia, Dehiscence, and Stenosis. Proc Am Thorac Soc. 2009;6(1):79–93.PubMedCrossRef Santacruz JF, Mehta AC. Airway Complications and Management after Lung Transplantation: Ischemia, Dehiscence, and Stenosis. Proc Am Thorac Soc. 2009;6(1):79–93.PubMedCrossRef
30.
Zurück zum Zitat DeFreitas MR, McAdams HP, Azfar Ali H, Iranmanesh AM, Chalian H. Complications of Lung Transplantation: Update on Imaging Manifestations and Management. Radiol Cardiothorac Imaging. 2021;3(4):e190252.PubMedPubMedCentralCrossRef DeFreitas MR, McAdams HP, Azfar Ali H, Iranmanesh AM, Chalian H. Complications of Lung Transplantation: Update on Imaging Manifestations and Management. Radiol Cardiothorac Imaging. 2021;3(4):e190252.PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Chia E, Babawale SN. Imaging features of intrathoracic complications of lung transplantation: What the radiologists need to know. World J Radiol. 2017;9(12):438–47.PubMedPubMedCentralCrossRef Chia E, Babawale SN. Imaging features of intrathoracic complications of lung transplantation: What the radiologists need to know. World J Radiol. 2017;9(12):438–47.PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat Gill RR, Poh AC, Camp PC, Allen JM, Delano MT, Jacobson FL, et al. MDCT Evaluation of Central Airway and Vascular Complications of Lung Transplantation. Am J Roentgenol. 2008;191(4):1046–56.CrossRef Gill RR, Poh AC, Camp PC, Allen JM, Delano MT, Jacobson FL, et al. MDCT Evaluation of Central Airway and Vascular Complications of Lung Transplantation. Am J Roentgenol. 2008;191(4):1046–56.CrossRef
33.
Zurück zum Zitat Lee E, Litmanovich D, Boiselle P. Multidetector CT Evaluation of Tracheobronchomalacia. Radiol Clin North Am. 2009;47(2):261–9.PubMedCrossRef Lee E, Litmanovich D, Boiselle P. Multidetector CT Evaluation of Tracheobronchomalacia. Radiol Clin North Am. 2009;47(2):261–9.PubMedCrossRef
34.
Zurück zum Zitat Aslam A, Cardenas JDL, Morrison R, Lagisetty K, Litmanovich D, Sella E, et al. Tracheobronchomalacia and Excessive Dynamic Airway Collapse: Current Concepts and Future Directions. Radiographics. 2022;42(4):1012–27.PubMedCrossRef Aslam A, Cardenas JDL, Morrison R, Lagisetty K, Litmanovich D, Sella E, et al. Tracheobronchomalacia and Excessive Dynamic Airway Collapse: Current Concepts and Future Directions. Radiographics. 2022;42(4):1012–27.PubMedCrossRef
36.
Zurück zum Zitat Batra K, Chamarthy MR, Reddick M, Roda MS, Wait M, Kalva SP. Diagnosis and interventions of vascular complications in lung transplant. Cardiovasc Diagn Ther. 2018;8(3):378–86.PubMedPubMedCentralCrossRef Batra K, Chamarthy MR, Reddick M, Roda MS, Wait M, Kalva SP. Diagnosis and interventions of vascular complications in lung transplant. Cardiovasc Diagn Ther. 2018;8(3):378–86.PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Izbicki G, Bairey O, Shitrit D, Lahav J, Kramer MR. Increased Thromboembolic Events After Lung Transplantation. Chest. 2006;129(2):412–6.PubMedCrossRef Izbicki G, Bairey O, Shitrit D, Lahav J, Kramer MR. Increased Thromboembolic Events After Lung Transplantation. Chest. 2006;129(2):412–6.PubMedCrossRef
38.
Zurück zum Zitat Burns KEA, Iacono AT. Pulmonary embolism on postmortem examination: an under-recognized complication in lung-transplant recipients? Transplantation. 2004;77(5):692–8.PubMedCrossRef Burns KEA, Iacono AT. Pulmonary embolism on postmortem examination: an under-recognized complication in lung-transplant recipients? Transplantation. 2004;77(5):692–8.PubMedCrossRef
39.
Zurück zum Zitat Ahya V, McShane P, Baz M, Valentine V, Arcasoy S, Love R, et al. Increased risk of venous thromboembolism with a sirolimus-based immunosuppression regimen in lung transplantation. J Heart Lung Transplant. 2011;30(2):175–81.PubMedCrossRef Ahya V, McShane P, Baz M, Valentine V, Arcasoy S, Love R, et al. Increased risk of venous thromboembolism with a sirolimus-based immunosuppression regimen in lung transplantation. J Heart Lung Transplant. 2011;30(2):175–81.PubMedCrossRef
40.
Zurück zum Zitat Yegen HA, Lederer DJ, Barr RG, Wilt JS, Fang Y, Bagiella E, et al. Risk Factors for Venous Thromboembolism After Lung Transplantation. Chest. 2007;132(2):547–53.PubMedCrossRef Yegen HA, Lederer DJ, Barr RG, Wilt JS, Fang Y, Bagiella E, et al. Risk Factors for Venous Thromboembolism After Lung Transplantation. Chest. 2007;132(2):547–53.PubMedCrossRef
41.
Zurück zum Zitat Krishnam MS, Suh RD, Tomasian A, Goldin JG, Lai C, Brown K, et al. Postoperative Complications of Lung Transplantation: Radiologic Findings along a Time Continuum. Radiographics. 2007;27(4):957–74.PubMedCrossRef Krishnam MS, Suh RD, Tomasian A, Goldin JG, Lai C, Brown K, et al. Postoperative Complications of Lung Transplantation: Radiologic Findings along a Time Continuum. Radiographics. 2007;27(4):957–74.PubMedCrossRef
42.
Zurück zum Zitat Aboagye JK, Hayanga JWA, Lau BD, Bush EL, Shaffer DL, Hobson DB, et al. Venous Thromboembolism in Patients Hospitalized for Lung Transplantation. Ann Thorac Surg. 2018;105(4):1071–6.PubMedCrossRef Aboagye JK, Hayanga JWA, Lau BD, Bush EL, Shaffer DL, Hobson DB, et al. Venous Thromboembolism in Patients Hospitalized for Lung Transplantation. Ann Thorac Surg. 2018;105(4):1071–6.PubMedCrossRef
43.
Zurück zum Zitat Dorry M, Shofer S, Mahmood K, Glisinski K, Snyder L. Post-Transplant Pulmonary Embolism Is Associated With Allograft Dysfunction and Worse Survival. Chest. 2016;150(4, Supplement):1310A.CrossRef Dorry M, Shofer S, Mahmood K, Glisinski K, Snyder L. Post-Transplant Pulmonary Embolism Is Associated With Allograft Dysfunction and Worse Survival. Chest. 2016;150(4, Supplement):1310A.CrossRef
44.
Zurück zum Zitat Krivokuca I, van de Graaf EA, van Kessel DA, van den Bosch JMM, Grutters JC, Kwakkel-van Erp JM. Pulmonary Embolism and Pulmonary Infarction After Lung Transplantation. Clin Appl Thromb. 2011;17(4):421–4.CrossRef Krivokuca I, van de Graaf EA, van Kessel DA, van den Bosch JMM, Grutters JC, Kwakkel-van Erp JM. Pulmonary Embolism and Pulmonary Infarction After Lung Transplantation. Clin Appl Thromb. 2011;17(4):421–4.CrossRef
45.
Zurück zum Zitat Koroscil MT, Hauser TR. Acute pulmonary embolism leading to cavitation and large pulmonary abscess: A rare complication of pulmonary infarction. Respir Med Case Rep. 2016;18(20):72–4. Koroscil MT, Hauser TR. Acute pulmonary embolism leading to cavitation and large pulmonary abscess: A rare complication of pulmonary infarction. Respir Med Case Rep. 2016;18(20):72–4.
46.
Zurück zum Zitat Kumar N, Hussain N, Kumar J, Essandoh M, Bhatt A, Awad H, et al. Evaluating the Impact of Pulmonary Artery Obstruction After Lung Transplant Surgery: A Systematic Review and Meta-analysis. Transplantation. 2021;104(4):711–22.CrossRef Kumar N, Hussain N, Kumar J, Essandoh M, Bhatt A, Awad H, et al. Evaluating the Impact of Pulmonary Artery Obstruction After Lung Transplant Surgery: A Systematic Review and Meta-analysis. Transplantation. 2021;104(4):711–22.CrossRef
47.
Zurück zum Zitat Kumar N, Essandoh M, Bhatt A, Whitson BA, Sawyer TR, Flores A, et al. Pulmonary cuff dysfunction after lung transplant surgery: A systematic review of the evidence and analysis of its clinical implications. J Heart Lung Transplant. 2019;38(5):530–44.PubMedCrossRef Kumar N, Essandoh M, Bhatt A, Whitson BA, Sawyer TR, Flores A, et al. Pulmonary cuff dysfunction after lung transplant surgery: A systematic review of the evidence and analysis of its clinical implications. J Heart Lung Transplant. 2019;38(5):530–44.PubMedCrossRef
48.
49.
Zurück zum Zitat Jing L, Chen W, Zhai Z, Pan X, Tao X, Cao L, et al. Pulmonary vein stenosis after lung transplantation: a case report and literature review. Ann Transl Med. 2021;9(2):181.PubMedPubMedCentralCrossRef Jing L, Chen W, Zhai Z, Pan X, Tao X, Cao L, et al. Pulmonary vein stenosis after lung transplantation: a case report and literature review. Ann Transl Med. 2021;9(2):181.PubMedPubMedCentralCrossRef
50.
Zurück zum Zitat Kayawake H, Aoyama A, Kinoshita H, Yoneda T, Baba S, Teramoto Y, et al. Diameter of the dilated main pulmonary artery in patients with pulmonary hypertension decreases after lung transplantation. Surg Today. 2020;50(3):275–83.PubMedCrossRef Kayawake H, Aoyama A, Kinoshita H, Yoneda T, Baba S, Teramoto Y, et al. Diameter of the dilated main pulmonary artery in patients with pulmonary hypertension decreases after lung transplantation. Surg Today. 2020;50(3):275–83.PubMedCrossRef
51.
Zurück zum Zitat Sarashina T, Nakamura K, Akagi S, Oto T, Oe H, Ejiri K, et al. Reverse Right Ventricular Remodeling After Lung Transplantation in Patients With Pulmonary Arterial Hypertension Under Combination Therapy of Targeted Medical Drugs. Circ J. 2017;81(3):383–90.PubMedCrossRef Sarashina T, Nakamura K, Akagi S, Oto T, Oe H, Ejiri K, et al. Reverse Right Ventricular Remodeling After Lung Transplantation in Patients With Pulmonary Arterial Hypertension Under Combination Therapy of Targeted Medical Drugs. Circ J. 2017;81(3):383–90.PubMedCrossRef
53.
Zurück zum Zitat Diamond J, Arcasoy A, Kennedy C, Eberlein M, Singer J, Patterson G, et al. Report of the International Society for Heart and Lung Transplantation Working Group on Primary Lung Graft Dysfunction, part II: Epidemiology, risk factors, and outcomes—A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2017;36(10):1103–13.CrossRef Diamond J, Arcasoy A, Kennedy C, Eberlein M, Singer J, Patterson G, et al. Report of the International Society for Heart and Lung Transplantation Working Group on Primary Lung Graft Dysfunction, part II: Epidemiology, risk factors, and outcomes—A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2017;36(10):1103–13.CrossRef
54.
Zurück zum Zitat Daoud D, Alberty LC, Wei Q, Mendez CH, Virk MHM, Mase J, et al. Incidence of primary graft dysfunction is higher according to the new ISHLT 2016 guidelines and correlates with clinical and molecular risk factors. J Thorac Dis. 2021 Jun [cited 2022 Nov 7];13(6). Available from: https://jtd.amegroups.com/article/view/52865. Daoud D, Alberty LC, Wei Q, Mendez CH, Virk MHM, Mase J, et al. Incidence of primary graft dysfunction is higher according to the new ISHLT 2016 guidelines and correlates with clinical and molecular risk factors. J Thorac Dis. 2021 Jun [cited 2022 Nov 7];13(6). Available from: https://​jtd.​amegroups.​com/​article/​view/​52865.
55.
Zurück zum Zitat Diamond JM, Lee JC, Kawut SM, Shah RJ, Localio AR, Bellamy SL, et al. Clinical Risk Factors for Primary Graft Dysfunction after Lung Transplantation. Am J Respir Crit Care Med. 2013;187(5):527–34.PubMedPubMedCentralCrossRef Diamond JM, Lee JC, Kawut SM, Shah RJ, Localio AR, Bellamy SL, et al. Clinical Risk Factors for Primary Graft Dysfunction after Lung Transplantation. Am J Respir Crit Care Med. 2013;187(5):527–34.PubMedPubMedCentralCrossRef
56.
Zurück zum Zitat Van Slambrouck J, Van Raemdonck D, Vos R, Vanluyten C, Vanstapel A, Prisciandaro E, et al. A Focused Review on Primary Graft Dysfunction after Clinical Lung Transplantation: A Multilevel Syndrome. Cells. 2022;11(4):745.PubMedPubMedCentralCrossRef Van Slambrouck J, Van Raemdonck D, Vos R, Vanluyten C, Vanstapel A, Prisciandaro E, et al. A Focused Review on Primary Graft Dysfunction after Clinical Lung Transplantation: A Multilevel Syndrome. Cells. 2022;11(4):745.PubMedPubMedCentralCrossRef
57.
Zurück zum Zitat Kolaitis NA. Lung Transplantation for Pulmonary Arterial Hypertension. Chest. 2023;S0012–3692(23):00649–59. Kolaitis NA. Lung Transplantation for Pulmonary Arterial Hypertension. Chest. 2023;S0012–3692(23):00649–59.
58.
Zurück zum Zitat Garrido G, Dhillon GS. Medical Course and Complications After Lung Transplantation. Psychosoc Care End-Stage Organ Dis Transpl Patients. 2018;23:279–88. Garrido G, Dhillon GS. Medical Course and Complications After Lung Transplantation. Psychosoc Care End-Stage Organ Dis Transpl Patients. 2018;23:279–88.
59.
Zurück zum Zitat Karkhanis VS, Joshi JM. Pleural effusion: diagnosis, treatment, and management. Open Access Emerg Med OAEM. 2012;22(4):31–52.CrossRef Karkhanis VS, Joshi JM. Pleural effusion: diagnosis, treatment, and management. Open Access Emerg Med OAEM. 2012;22(4):31–52.CrossRef
60.
Zurück zum Zitat Jacob S, Meneses A, Landolfo K, El-Sayed Ahmed M, Makey IA, Pham SM, et al. Incidence, Management, and Outcomes of Chylothorax after Lung Transplantation: A Single-center Experience. Cureus. 2019;11(7):e5190.PubMedPubMedCentral Jacob S, Meneses A, Landolfo K, El-Sayed Ahmed M, Makey IA, Pham SM, et al. Incidence, Management, and Outcomes of Chylothorax after Lung Transplantation: A Single-center Experience. Cureus. 2019;11(7):e5190.PubMedPubMedCentral
61.
Zurück zum Zitat Wahidi M, Willner D, Snyder L, Curl J, Hardison J, Chia J, et al. Diagnosis and Outcome of Early Pleural Space Infection Following Lung Transplantation. Chest. 2009;135(2):484–91.PubMedCrossRef Wahidi M, Willner D, Snyder L, Curl J, Hardison J, Chia J, et al. Diagnosis and Outcome of Early Pleural Space Infection Following Lung Transplantation. Chest. 2009;135(2):484–91.PubMedCrossRef
62.
Zurück zum Zitat Nunley DR, Grgurich WF, Keenan RJ, Dauber JH. Empyema complicating successful lung transplantation. Chest. 1999;115(5):1312–5.PubMedCrossRef Nunley DR, Grgurich WF, Keenan RJ, Dauber JH. Empyema complicating successful lung transplantation. Chest. 1999;115(5):1312–5.PubMedCrossRef
65.
Zurück zum Zitat Lehto JT, Koskinen PK, Anttila VJ, Lautenschlager I, Lemström K, Sipponen J, et al. Bronchoscopy in the diagnosis and surveillance of respiratory infections in lung and heart–lung transplant recipients. Transpl Int. 2005;18(5):562–71.PubMedCrossRef Lehto JT, Koskinen PK, Anttila VJ, Lautenschlager I, Lemström K, Sipponen J, et al. Bronchoscopy in the diagnosis and surveillance of respiratory infections in lung and heart–lung transplant recipients. Transpl Int. 2005;18(5):562–71.PubMedCrossRef
66.
Zurück zum Zitat Kotloff RM, Ahya VN. Medical complications of lung transplantation. Eur Respir J. 2004;23(2):334–42.PubMedCrossRef Kotloff RM, Ahya VN. Medical complications of lung transplantation. Eur Respir J. 2004;23(2):334–42.PubMedCrossRef
67.
Zurück zum Zitat De Soyza A, Corris PA. Lung transplantation and the Burkholderia cepacia complex. J Heart Lung Transplant. 2003;22(9):954–8.PubMedCrossRef De Soyza A, Corris PA. Lung transplantation and the Burkholderia cepacia complex. J Heart Lung Transplant. 2003;22(9):954–8.PubMedCrossRef
68.
Zurück zum Zitat Aris RM, Routh JC, LiPUMA JJ, Heath DG, Gilligan PH. Lung Transplantation for Cystic Fibrosis Patients with Burkholderia cepacia Complex. Am J Respir Crit Care Med. 2001;164(11):2102–6.PubMedCrossRef Aris RM, Routh JC, LiPUMA JJ, Heath DG, Gilligan PH. Lung Transplantation for Cystic Fibrosis Patients with Burkholderia cepacia Complex. Am J Respir Crit Care Med. 2001;164(11):2102–6.PubMedCrossRef
69.
Zurück zum Zitat Chaparro C, Maurer J, Gutierrez C, Krajden M, Chan C, Winton T, et al. Infection with Burkholderia cepacia in Cystic Fibrosis. Am J Respir Crit Care Med. 2001;163(1):43–8.PubMedCrossRef Chaparro C, Maurer J, Gutierrez C, Krajden M, Chan C, Winton T, et al. Infection with Burkholderia cepacia in Cystic Fibrosis. Am J Respir Crit Care Med. 2001;163(1):43–8.PubMedCrossRef
70.
Zurück zum Zitat Averill S, Lubner M, Menias C, Bhalla S, Mellnick V, Kennedy T, et al. Multisystem Imaging Findings of Cystic Fibrosis in Adults: Recognizing Typical and Atypical Patterns of Disease. Am J Roentgenol. 2017;209(1):3–18.CrossRef Averill S, Lubner M, Menias C, Bhalla S, Mellnick V, Kennedy T, et al. Multisystem Imaging Findings of Cystic Fibrosis in Adults: Recognizing Typical and Atypical Patterns of Disease. Am J Roentgenol. 2017;209(1):3–18.CrossRef
71.
Zurück zum Zitat Ng MY, Flight W, Smith E. Pulmonary complications of cystic fibrosis. Clin Radiol. 2014;69(3):e153-62.PubMedCrossRef Ng MY, Flight W, Smith E. Pulmonary complications of cystic fibrosis. Clin Radiol. 2014;69(3):e153-62.PubMedCrossRef
72.
Zurück zum Zitat Shafiq I, Carroll MP, Nightingale JA, Daniels TVW. Cepacia syndrome in a cystic fibrosis patient colonised with Burkholderia multivorans. Case Rep. 2011;2011:bcr0820103296. Shafiq I, Carroll MP, Nightingale JA, Daniels TVW. Cepacia syndrome in a cystic fibrosis patient colonised with Burkholderia multivorans. Case Rep. 2011;2011:bcr0820103296.
73.
Zurück zum Zitat Collins J, Müller NL, Kazerooni EA, Paciocco G. CT Findings of Pneumonia After Lung Transplantation. Am J Roentgenol. 2000;175(3):811–8.CrossRef Collins J, Müller NL, Kazerooni EA, Paciocco G. CT Findings of Pneumonia After Lung Transplantation. Am J Roentgenol. 2000;175(3):811–8.CrossRef
74.
Zurück zum Zitat Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases. Am J Respir Crit Care Med. 2007;175(4):367–416.PubMedCrossRef Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases. Am J Respir Crit Care Med. 2007;175(4):367–416.PubMedCrossRef
75.
Zurück zum Zitat Kamp JC, Hinrichs JB, Fuge J, Ewen R, Gottlieb J. COVID-19 in lung transplant recipients—Risk prediction and outcomes. PLoS ONE. 2021;16(10):e0257807.PubMedPubMedCentralCrossRef Kamp JC, Hinrichs JB, Fuge J, Ewen R, Gottlieb J. COVID-19 in lung transplant recipients—Risk prediction and outcomes. PLoS ONE. 2021;16(10):e0257807.PubMedPubMedCentralCrossRef
76.
Zurück zum Zitat Messika J, Eloy P, Roux A, Hirschi S, Nieves A, Le Pavec J, et al. COVID-19 in Lung Transplant Recipients. Transplantation. 2021;105(1):177–86.PubMedCrossRef Messika J, Eloy P, Roux A, Hirschi S, Nieves A, Le Pavec J, et al. COVID-19 in Lung Transplant Recipients. Transplantation. 2021;105(1):177–86.PubMedCrossRef
77.
Zurück zum Zitat Roosma E, van Gemert JP, de Zwart AES, van Leer-Buter CC, Hellemons ME, Berg EM, et al. The effect of COVID-19 on transplant function and development of CLAD in lung transplant patients: A multicenter experience. J Heart Lung Transplant. 2022;41(9):1237–47.PubMedPubMedCentralCrossRef Roosma E, van Gemert JP, de Zwart AES, van Leer-Buter CC, Hellemons ME, Berg EM, et al. The effect of COVID-19 on transplant function and development of CLAD in lung transplant patients: A multicenter experience. J Heart Lung Transplant. 2022;41(9):1237–47.PubMedPubMedCentralCrossRef
78.
Zurück zum Zitat Hage R, Schuurmans MM. COVID-Related Chronic Allograft Dysfunction in Lung Transplant Recipients: Long-Term Follow-up Results from Infections Occurring in the Pre-vaccination Era. Transplantology. 2022;3(4):275–82.CrossRef Hage R, Schuurmans MM. COVID-Related Chronic Allograft Dysfunction in Lung Transplant Recipients: Long-Term Follow-up Results from Infections Occurring in the Pre-vaccination Era. Transplantology. 2022;3(4):275–82.CrossRef
79.
Zurück zum Zitat Allyn PR, Duffy EL, Humphries RM, Injean P, Weigt SS, Saggar R, et al. Graft loss and CLAD onset is hastened by viral pneumonia after lung transplantation. Transplantation. 2016;100(11):2424–31.PubMedPubMedCentralCrossRef Allyn PR, Duffy EL, Humphries RM, Injean P, Weigt SS, Saggar R, et al. Graft loss and CLAD onset is hastened by viral pneumonia after lung transplantation. Transplantation. 2016;100(11):2424–31.PubMedPubMedCentralCrossRef
80.
Zurück zum Zitat Mahan LD, Lill I, Halverson Q, Mohanka MR, Lawrence A, Joerns J, et al. Post-infection pulmonary sequelae after COVID-19 among patients with lung transplantation. Transpl Infect Dis. 2021;23(6): e13739.PubMedPubMedCentralCrossRef Mahan LD, Lill I, Halverson Q, Mohanka MR, Lawrence A, Joerns J, et al. Post-infection pulmonary sequelae after COVID-19 among patients with lung transplantation. Transpl Infect Dis. 2021;23(6): e13739.PubMedPubMedCentralCrossRef
81.
Zurück zum Zitat Levine DJ, Glanville AR, Aboyoun C, Belperio J, Benden C, Berry GJ, et al. Antibody-mediated rejection of the lung: A consensus report of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2016;35(4):397–406.PubMedCrossRef Levine DJ, Glanville AR, Aboyoun C, Belperio J, Benden C, Berry GJ, et al. Antibody-mediated rejection of the lung: A consensus report of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2016;35(4):397–406.PubMedCrossRef
82.
Zurück zum Zitat Yusen RD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Goldfarb SB, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Lung and Heart-Lung Transplantation Report—2015; Focus Theme: Early Graft Failure. J Heart Lung Transplant. 2015;34(10):1264–77.PubMedCrossRef Yusen RD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Goldfarb SB, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Lung and Heart-Lung Transplantation Report—2015; Focus Theme: Early Graft Failure. J Heart Lung Transplant. 2015;34(10):1264–77.PubMedCrossRef
83.
Zurück zum Zitat Gotway MB, Dawn SK, Sellami D, Golden JA, Reddy GP, Keith FM, et al. Acute Rejection Following Lung Transplantation: Limitations in Accuracy of Thin-Section CT for Diagnosis. Radiology. 2001;221(1):207–12.PubMedCrossRef Gotway MB, Dawn SK, Sellami D, Golden JA, Reddy GP, Keith FM, et al. Acute Rejection Following Lung Transplantation: Limitations in Accuracy of Thin-Section CT for Diagnosis. Radiology. 2001;221(1):207–12.PubMedCrossRef
84.
86.
Zurück zum Zitat Otani S, Davis AK, Cantwell L, Ivulich S, Pham A, Paraskeva MA, et al. Evolving experience of treating antibody-mediated rejection following lung transplantation. Transpl Immunol. 2014;31(2):75–80.PubMedCrossRef Otani S, Davis AK, Cantwell L, Ivulich S, Pham A, Paraskeva MA, et al. Evolving experience of treating antibody-mediated rejection following lung transplantation. Transpl Immunol. 2014;31(2):75–80.PubMedCrossRef
88.
Zurück zum Zitat Stewart S, Fishbein MC, Snell GI, Berry GJ, Boehler A, Burke MM, et al. Revision of the 1996 Working Formulation for the Standardization of Nomenclature in the Diagnosis of Lung Rejection. J Heart Lung Transplant. 2007;26(12):1229–42.PubMedCrossRef Stewart S, Fishbein MC, Snell GI, Berry GJ, Boehler A, Burke MM, et al. Revision of the 1996 Working Formulation for the Standardization of Nomenclature in the Diagnosis of Lung Rejection. J Heart Lung Transplant. 2007;26(12):1229–42.PubMedCrossRef
89.
Zurück zum Zitat Verleden GM, Glanville AR, Lease ED, Fisher AJ, Calabrese F, Corris PA, et al. Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment-A consensus report from the Pulmonary Council of the ISHLT. J Heart Lung Transplant. 2019;38(5):493–503.PubMedCrossRef Verleden GM, Glanville AR, Lease ED, Fisher AJ, Calabrese F, Corris PA, et al. Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment-A consensus report from the Pulmonary Council of the ISHLT. J Heart Lung Transplant. 2019;38(5):493–503.PubMedCrossRef
90.
Zurück zum Zitat Thangavelu T, Lyden E, Shivaswamy V. A Retrospective Study of Glucagon-Like Peptide 1 Receptor Agonists for the Management of Diabetes After Transplantation. Diabetes Ther. 2020;11(4):987–94.PubMedPubMedCentralCrossRef Thangavelu T, Lyden E, Shivaswamy V. A Retrospective Study of Glucagon-Like Peptide 1 Receptor Agonists for the Management of Diabetes After Transplantation. Diabetes Ther. 2020;11(4):987–94.PubMedPubMedCentralCrossRef
91.
Zurück zum Zitat Verleden SE, Vos R, Vanaudenaerde BM, Verleden GM. Chronic lung allograft dysfunction phenotypes and treatment. J Thorac Dis. 2017;9(8):2650–9.PubMedPubMedCentralCrossRef Verleden SE, Vos R, Vanaudenaerde BM, Verleden GM. Chronic lung allograft dysfunction phenotypes and treatment. J Thorac Dis. 2017;9(8):2650–9.PubMedPubMedCentralCrossRef
92.
Zurück zum Zitat Sharifi H, Guenther ZD, Leung ANC, Johnston L, Lai YK, Hsu JL, et al. Head-to-head Comparison of Qualitative Radiologist Assessment With Automated Quantitative Computed Tomography Analysis for Bronchiolitis Obliterans Syndrome After Hematopoietic Cell Transplantation. J Thorac Imaging. 2022;37(2):109–16.PubMedCrossRef Sharifi H, Guenther ZD, Leung ANC, Johnston L, Lai YK, Hsu JL, et al. Head-to-head Comparison of Qualitative Radiologist Assessment With Automated Quantitative Computed Tomography Analysis for Bronchiolitis Obliterans Syndrome After Hematopoietic Cell Transplantation. J Thorac Imaging. 2022;37(2):109–16.PubMedCrossRef
93.
Zurück zum Zitat Gottlieb J, Verleden GM, Perchl M, Valtin C, Vallee A, Brugière O, et al. Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunction—A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial. PLoS ONE. 2021;16(12):e0260881.PubMedPubMedCentralCrossRef Gottlieb J, Verleden GM, Perchl M, Valtin C, Vallee A, Brugière O, et al. Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunction—A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial. PLoS ONE. 2021;16(12):e0260881.PubMedPubMedCentralCrossRef
94.
Zurück zum Zitat Sato M, Waddell TK, Wagnetz U, Roberts HC, Hwang DM, Haroon A, et al. Restrictive allograft syndrome (RAS): A novel form of chronic lung allograft dysfunction. J Heart Lung Transplant. 2011;30(7):735–42.PubMedCrossRef Sato M, Waddell TK, Wagnetz U, Roberts HC, Hwang DM, Haroon A, et al. Restrictive allograft syndrome (RAS): A novel form of chronic lung allograft dysfunction. J Heart Lung Transplant. 2011;30(7):735–42.PubMedCrossRef
95.
Zurück zum Zitat Ofek E, Sato M, Saito T, Wagnetz U, Roberts HC, Chaparro C, et al. Restrictive allograft syndrome post lung transplantation is characterized by pleuroparenchymal fibroelastosis. Mod Pathol. 2013;26(3):350–6.PubMedCrossRef Ofek E, Sato M, Saito T, Wagnetz U, Roberts HC, Chaparro C, et al. Restrictive allograft syndrome post lung transplantation is characterized by pleuroparenchymal fibroelastosis. Mod Pathol. 2013;26(3):350–6.PubMedCrossRef
96.
Zurück zum Zitat Collins J, Hartman MJ, Warner TF, Müller NL, Kazerooni EA, McAdams HP, et al. Frequency and CT Findings of Recurrent Disease after Lung Transplantation. Radiology. 2001;219(2):503–9.PubMedCrossRef Collins J, Hartman MJ, Warner TF, Müller NL, Kazerooni EA, McAdams HP, et al. Frequency and CT Findings of Recurrent Disease after Lung Transplantation. Radiology. 2001;219(2):503–9.PubMedCrossRef
97.
Zurück zum Zitat Scallan C, Venado A, Han L, Xu H, Mulligan M, Raghu G. Recurrent Pulmonary Fibrosis in a Lung Allograft Secondary to De Novo Antisynthetase Syndrome. Ann Am Thorac Soc. 2020;17(7):901–4.PubMedCrossRef Scallan C, Venado A, Han L, Xu H, Mulligan M, Raghu G. Recurrent Pulmonary Fibrosis in a Lung Allograft Secondary to De Novo Antisynthetase Syndrome. Ann Am Thorac Soc. 2020;17(7):901–4.PubMedCrossRef
100.
Zurück zum Zitat Borhani AA, Hosseinzadeh K, Almusa O, Furlan A, Nalesnik M. Imaging of Posttransplantation Lymphoproliferative Disorder after Solid Organ Transplantation. Radiographics. 2009;29(4):981–1000.PubMedCrossRef Borhani AA, Hosseinzadeh K, Almusa O, Furlan A, Nalesnik M. Imaging of Posttransplantation Lymphoproliferative Disorder after Solid Organ Transplantation. Radiographics. 2009;29(4):981–1000.PubMedCrossRef
Metadaten
Titel
Pulmonary transplant complications: a radiologic review
verfasst von
Samuel Friedlander
Brian Pogatchnik
Yuka Furuya
Tadashi Allen
Publikationsdatum
01.12.2024
Verlag
BioMed Central
Erschienen in
Journal of Cardiothoracic Surgery / Ausgabe 1/2024
Elektronische ISSN: 1749-8090
DOI
https://doi.org/10.1186/s13019-024-02731-w

Weitere Artikel der Ausgabe 1/2024

Journal of Cardiothoracic Surgery 1/2024 Zur Ausgabe

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Häusliche Gewalt Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.